NYSE: ABBVAbbvie Inc Stock
$195.65+1.46 (+0.75%)
Updated Oct 14, 2024
ABBV Price
$195.65
Fair Value Price
N/A
Market Cap
$345.59B
52 Week Low
$135.85
52 Week High
$199.95
P/E
65.22x
P/B
50.99x
P/S
5.51x
PEG
1x
Dividend Yield
2.38%
Revenue
$55.00B
Earnings
$5.34B
Gross Margin
62.8%
Operating Margin
15.98%
Profit Margin
9.7%
Debt to Equity
19.93
Operating Cash Flow
$19B
Beta
0.54
Next Earnings
Oct 30, 2024
Ex-Dividend
Oct 15, 2024
Next Dividend
Nov 15, 2024
ABBV Overview
AbbVie Inc. is a research focused biopharmaceutical company. The company produces pharmaceutical drugs for immunology, chronic kidney disease, hepatitis C, women's health, oncology, and neuroscience. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, virology, and other serious health conditions. The company was spun off from Abbott Laboratories in 2013 and is headquartered in North Chicago, IL.
Zen Score
–
Industry Average (37)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ABBV scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ABBV ($195.65) is trading above its intrinsic value of $89.06, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ABBV is poor value based on its earnings relative to its share price (65.22x), compared to the US market average (27.44x)
P/E vs Market Valuation
ABBV is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more ABBV due diligence checks available for Premium users.
Be the first to know about important ABBV news, forecast changes, insider trades & much more!
ABBV News
Valuation
ABBV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
65.22x
Industry
50.29x
Market
27.44x
ABBV is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ABBV is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
ABBV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
50.99x
Industry
6.84x
ABBV is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ABBV price to earnings growth (PEG)
For valuing profitable companies with growth potential
ABBV is good value based... subscribe to Premium to read more.
PEG Value Valuation
ABBV's financial health
Profit margin
Revenue
$14.5B
Net Income
$1.4B
Profit Margin
9.5%
ABBV's Earnings (EBIT) of $8.79B... subscribe to Premium to read more.
Interest Coverage Financials
ABBV's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$141.9B
Liabilities
$135.1B
Debt to equity
19.93
ABBV's short-term liabilities ($41.92B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ABBV's long-term liabilities ($93.20B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ABBV's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ABBV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$2.3B
Investing
-$1.1B
Financing
-$6.1B
ABBV's operating cash flow ($18.64B)... subscribe to Premium to read more.
Debt Coverage Financials
ABBV vs General Drug Manufacturer Stocks
Abbvie Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.